Characterization of Inflammatory Bowel Disease Heterogeneity Using Serum Proteomics: A Multicenter Study - Scorecard - MDSpire

Characterization of Inflammatory Bowel Disease Heterogeneity Using Serum Proteomics: A Multicenter Study

  • By

  • Benita Salomon

  • Padhmanand Sudhakar

  • Daniel Bergemalm

  • Erik Andersson

  • Olle Grännö

  • Marie Carlson

  • Charlotte R H Hedin

  • Johan D Söderholm

  • Lena Öhman

  • the COLLIBRI Consortium the BIO IBD Consortium

  • Ryan C Ungaro

  • Konrad Aden

  • Geert D’Haens

  • Mark S Silverberg

  • Sven Almer

  • Francesca Bresso

  • Adam Carstens

  • Mauro D’Amato

  • Carl Eriksson

  • Henrik Hjortswang

  • Åsa V Keita

  • Maria Ling Lundström

  • Maria K Magnusson

  • Jóhann P Hreinsson

  • Hans Strid

  • Carl Mårten Lindqvist

  • Robert Kruse

  • Dirk Repsilber

  • Bram Verstockt

  • Séverine Vermeire

  • Jonas Halfvarson

  • November 4, 2024

  • 0 min

Share

Clinical Scorecard: Analysis of Serum Proteomics to Explore Heterogeneity in Inflammatory Bowel Disease: Findings from a Multicenter Investigation

At a Glance

CategoryDetail
ConditionInflammatory Bowel Disease (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC)
Key MechanismsInflammation-related serum proteins reflecting molecular heterogeneity and disease spectrum; post-transcriptional modifications assessed by proteomics
Target PopulationPatients diagnosed with IBD (CD, UC, and IBD-unclassified) across multiple European cohorts
Care SettingMulticenter clinical and research settings involving serum biomarker analysis

Key Highlights

  • Proteomic analysis identified distinct inflammatory serum protein patterns differentiating IBD subtypes and disease locations.
  • Findings support a continuous IBD spectrum with colonic CD positioned between UC and ileal CD rather than a strict CD vs UC dichotomy.
  • Classification models more accurately distinguished UC from ileal CD than from colonic CD, reflecting molecular overlap.

Guideline-Based Recommendations

Diagnosis

  • Use comprehensive clinical, microbiological, endoscopic, histological, and radiological evaluation to diagnose IBD.
  • Incorporate molecular profiling including serum proteomics to better characterize IBD heterogeneity and subphenotypes.

Management

  • Consider disease location and molecular subtype in therapeutic decision-making to optimize treatment strategies.
  • Recognize that current classifications may not capture full disease heterogeneity; personalized approaches are encouraged.

Monitoring & Follow-up

  • Monitor inflammatory serum protein levels as potential biomarkers to assess disease activity and subtype differentiation.

Risks

  • Be aware that combining all CD and UC patients in clinical trials without stratification may obscure treatment responses due to heterogeneity.

Patient & Prescribing Data

IBD patients with varying disease duration, activity, and treatment exposures from multiple European cohorts

Molecular stratification by serum proteomics may guide more precise therapeutic interventions tailored to disease location and subtype.

Clinical Best Practices

  • Apply the Montreal classification for initial phenotypic stratification but recognize its limitations in capturing molecular heterogeneity.
  • Utilize proteomic biomarker panels to refine disease classification and support personalized medicine approaches in IBD.
  • Incorporate multidisciplinary assessments combining clinical and molecular data for comprehensive patient evaluation.

References

Original Source(s)

Characterization of Inflammatory Bowel Disease Heterogeneity Using Serum Proteomics: A Multicenter Study

  • by Benita Salomon, Padhmanand Sudhakar, Daniel Bergemalm, Erik Andersson, Olle Grännö, Marie Carlson, Charlotte R H Hedin, Johan D Söderholm, Lena Öhman, the COLLIBRI Consortium the BIO IBD Consortium, Ryan C Ungaro, Konrad Aden, Geert D’Haens, Mark S Silverberg, Sven Almer, Francesca Bresso, Adam Carstens, Mauro D’Amato, Carl Eriksson, Henrik Hjortswang, Åsa V Keita, Maria Ling Lundström, Maria K Magnusson, Jóhann P Hreinsson, Hans Strid, Carl Mårten Lindqvist, Robert Kruse, Dirk Repsilber, Bram Verstockt, Séverine Vermeire, Jonas Halfvarson

  • November 4, 2024

Related Content

Therapeutic Approaches for Inflammatory Bowel Disease: The Role of Immunomodulators, Biologics, and 5-Aminosalicylates in Cardiovascular Risk Management

Advanced Crohn’s Therapies Show Similar Safety

Large claims analysis finds no significant differences in serious infections, blood clots, or major cardiovascular events across biologics and a Janus kinase inhibitor.

Evaluation of Tacrolimus in Ulcerative Colitis: A Retrospective Analysis of Factors Influencing Remission Induction and Maintenance